Login to Your Account



Rexgenero rises to the critical limb ischemia challenge

By Cormac Sheridan
Staff Writer

Wednesday, March 22, 2017

BARCELONA, Spain – What may well be Europe's least known cell therapy company has just begun a phase III trial of its lead program in a notoriously challenging indication. Rexgenero Ltd. began recruiting diabetic patients with CLI last week.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription